http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Yvelise Ferro ),( Ilaria Car ),( Elisa Mazza ),( Francesco Provenzano ),( Carmela Colica ),( Carlo Torti ),( Stefano Romeo ),( Arturo Pujia ),( Tiziana Montalcini ) 대한간학회 2017 Clinical and Molecular Hepatology(대한간학회지) Vol.23 No.3
Background/Aims: Although the detrimental effects of several dietary components on the promotion of non- alcoholic fatty liver disease are well known, no studies have assessed the role of dietary vitamin B6. Moreover, studies on the associations between dietary components or body composition indices and liver steatosis assessed by transient elastography are rare. Our aim was to identify the nutritional factors and anthropometric parameters associated with liver steatosis. Methods: In this cross-sectional study, we enrolled 168 individuals (35% obese) who underwent a liver steatosis assessment by Controlled Attenuation Parameter measurement and nutritional assessment. Results: Tertiles of vitamin B6 intake were positively associated with hepatic steatosis (B=1.89, P =0.026, confidence interval [CI] 0.03-0.80) as well as with triglycerides, glucose, alanine aminotransferase (ALT), and body mass index . In obese individuals, after multivariable analysis, the Controlled Attenuation Parameter score was still associated with triglycerides, ALT, and total protein intake (B=0.56, P=0.01, CI 0.10-1.02). Participants in tertile I (low intake) had a lower Controlled Attenuation Parameter than those in tertile III (P =0.01). Conclusions: We found a positive association between hepatic steatosis or Controlled Attenuation Parameter score and vitamin B6/total protein intake, probably related to the high intake of meat. Vitamin B6 might have a pathogenic role related to the increase of hepatic steatosis. (Clin Mol Hepatol 2017;23:249-259)
Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
Nadia Marascio,Angela Quirino,Giorgio Settimo Barreca,Luisa Galati,Chiara Costa,Vincenzo Pisani,Maria Mazzitelli,Giovanni Matera,Maria Carla Liberto,Alfredo Focà,Carlo Torti 대한간학회 2019 Clinical and Molecular Hepatology(대한간학회지) Vol.25 No.1
Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience.